Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

This trial tests a new drug called AST-3424 in people with advanced liver cancer (hepatocellular carcinoma, or HCC) whose tumours have a high level of an enzyme called AKR1C3. The drug is designed to target cancers with this specific enzyme. It's for patients whose cancer has continued to grow after previous immunotherapy treatments. **You may be eligible if...** - You have confirmed advanced liver cancer - Your cancer progressed during or after treatment with immune checkpoint inhibitors (a type of immunotherapy) - Your cancer is not suitable for surgery or local treatments - Your liver function is reasonably preserved (Child-Pugh A or B) - Your tumour tests show high AKR1C3 enzyme levels **You may NOT be eligible if...** - Your liver function is severely impaired - You have not received prior immunotherapy - You have certain other medical conditions preventing participation Talk to your doctor to see if this trial is right for you.